מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
CLADRIBINE (UNII: 47M74X9YT5) (CLADRIBINE - UNII:47M74X9YT5)
Pfizer Laboratories Div Pfizer Inc.
CLADRIBINE
CLADRIBINE 1 mg in 1 mL
PRESCRIPTION DRUG
Abbreviated New Drug Application
CLADRIBINE- CLADRIBINE INJECTION PFIZER LABORATORIES DIV PFIZER INC. ---------- CLARIBINE INJECTION FOR INTRAVENOUS INFUSION ONLY BOXED WARNING Cladribine Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received Cladribine Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of Cladribine (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies. DESCRIPTION Cladribine Injection (also commonly known as 2-chloro-2΄-deoxy- β -D-adenosine) is a synthetic antineoplastic agent for continuous intravenous infusion. It is a clear, colorless, sterile, preservative- free, isotonic solution. Cladribine Injection is available in single-use vials containing 10 mg (1 mg/mL) of cladribine, a chlorinated purine nucleoside analog. Each milliliter of Cladribine Injection contains 1 mg of the active ingredient and 9 mg (0.15 mEq) of sodium chloride as an inactive ingredient. The solution has a pH range of 5.5 to 8.0. Phosphoric acid and/or dibasic sodium phosphate may have been added to adjust the pH to 6.3±0.3. The chemical name for cladribine is 2-chloro-6-amino-9-(2-deoxy-β-D-erythropento-furanosyl) purine and the structure is represented below: cladribine MW 285.7 CLINICAL PHARMACOLOGY CELLULAR RESISTANCE AND SENSITIVITY: The selective toxicity of 2-chloro-2΄-deoxy-β-D-adenosine towards certain normal and malignant lymphocyte and monocy קרא את המסמך השלם